Bendamustine plus Rituximab Versus R‐CHOP as First‐Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study

BACKGROUND. Rituximab plus bendamustine (R‐B) has been demonstrated to improve outcomes and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and prednisone (R‐CHOP) in follicular lymphoma (FL). Nevertheless, in clinical practice, many centers still prefer R‐CHOP to R‐B in pati...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Mondello, Patrizia, Steiner, Normann, Willenbacher, Wolfgang, Cerchione, Claudio, Nappi, Davide, Mauro, Endri, Ferrero, Simone, Cuzzocrea, Salvatore, Mian, Michael
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2018
Konular:
Hematologic Malignancies
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5896707/
https://ncbi.nlm.nih.gov/pubmed/29317554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0037
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller